REGENXBIO RGX-314 Phase II ALTITUDE: 47% patients achieve ≥2-step DRSS improvement at 6 months vs 0% control

REGENXBIO Inc.

47% of RGX-314 patients in Cohort 1 showed ≥2-step DRSS improvement at 6 months vs 0% control; up from 33% at 3 months.
No drug-related serious adverse events or intraocular inflammation in 15 patients at 6 months; therapy well tolerated.
Among NPDR patients (severity 47-53), 57% achieved ≥2-step improvement; among PDR patients, 38% achieved improvement.
Enrollment ongoing for Cohorts 2 (5x10^11 GC/eye) and 3 (NAb-positive patients) with no prophylactic corticosteroid use.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.